Related Experiment Video
Updated: May 24, 2025
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.8K
Depolymerized peanut skin-derived proanthocyanidins alleviate cognitive dysfunction by inhibiting Aβ42 aggregation in
He Liu1, ZiYan Zhang1, XiaoQing Li1
1College of Life Sciences, Qingdao University, Qingdao 266071 China.
Food Research International (Ottawa, Ont.)
|March 1, 2025
Summary
Oligomeric proanthocyanidins (OPSP) derived from peanut skins show improved bioavailability and antioxidant capacity. OPSP effectively inhibits amyloid-beta aggregation and improves cognitive function in Alzheimer
Area of Science:
- Biochemistry
- Neuroscience
- Food Science
Background:
- Alzheimer's disease (AD) is linked to amyloid plaque aggregation.
- Peanut skin proanthocyanidins (PSP) have antioxidant properties but limited bioavailability.
- Depolymerization can enhance PSP's therapeutic potential.
Purpose of the Study:
- To optimize ultrasound-assisted alkaline depolymerization of PSP into OPSP.
- To characterize OPSP and compare its properties to PSP.
- To evaluate OPSP's efficacy in mitigating AD pathology both in vitro and in vivo.
Main Methods:
- Ultrasound-assisted alkaline depolymerization to produce OPSP.
- Physicochemical analysis of PSP and OPSP.
- In vitro amyloid-beta (Aβ42) inhibition assays.
- In vivo study using a rat model of Alzheimer's disease.
Main Results:
- Optimized depolymerization yielded OPSP with a reduced polymerization degree (2.87).
- OPSP demonstrated enhanced stability, antioxidant activity, and greater Aβ42 inhibition than PSP.
- OPSP improved memory, reduced neuroinflammation (IL-6, IL-1β, TNF-α), and decreased Aβ42 plaques in AD rats.
Conclusions:
- Optimized OPSP production enhances bioavailability and therapeutic potential.
- OPSP effectively targets key Alzheimer's disease pathologies.
- OPSP represents a promising natural therapeutic agent for Alzheimer's disease and a valuable use for peanut by-products.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
01:26Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
92
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
92